drugset / Trial / NCT00331604

Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes

NCT00331604

Phase 3 Terminated 618 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia, Europe and South America. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function tests, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart both in combination with insulin detemir in Type 2 Diabetes.

Timeline

Start
2006-08-31
Primary completion
2008-05-05
Completion
2008-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Other
Comparator insulin aspart Protein / enzyme biologic Subcutaneous
Background insulin detemir Protein / enzyme biologic Subcutaneous